Sort
30,917 grants matching “tumor microenvironment”
Unraveling the Impact of Extracellular Vesicle-Loaded FXR1 mRNA on Re-educating Cancer Microenvironment
$494,160Pradeep Chaluvally-Raghavan · Medical College Of Wisconsin · R01 · FY2025 · CA
Breast Cancer Intravoxel-incoherent-motion MRI Multisite (BRIMM) Study - Resubmission - 1
$494,118Eric Edward Sigmund · New York University School Of Medicine · UH3 · FY2024 · CA
Metabolic basis of ARID1A-mutated ovarian cancer
$494,032Rugang Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma
$493,987Darell D Bigner · Duke University · P01 · FY2020 · CA
Cell-Surface Interactions in Pathogenesis
$493,975Kenneth Yamada · National Institute Of Dental & Craniofacial Research · Z01 · FY2008 · DE
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
$493,963Mark R. Kelley · Indiana University Indianapolis · R01 · FY2017 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
$493,963Mark R. Kelley · Indiana University Indianapolis · R01 · FY2015 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
$493,963Mark R. Kelley · Indiana University Indianapolis · R01 · FY2013 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
$493,963Mark R. Kelley · Indiana University Indianapolis · R01 · FY2016 · CA
Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
$493,947Antonio Luigi Amelio · Univ Of North Carolina Chapel Hill · R01 · FY2021 · DE
Role of metabolic crosstalk in determining immunity during tumor progression
$493,895Ana C Anderson · Brigham And Women'S Hospital · R01 · FY2025 · CA
Molecular Mechanisms of Bladder Cancer Immunometabolism
$493,870Liuqing Yang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Investigating the role of metabolic rewiring in breast tumor innervation
$493,795Younghye Song · University Of Arkansas At Fayetteville · R37 · FY2025 · CA
Negative regulation of myeloid-derived suppressive cells in cancer
$493,744Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2018 · CA
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
$493,726Mark R. Kelley · Indiana University Indianapolis · R01 · FY2020 · CA
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
$493,726Mark R. Kelley · Indiana University Indianapolis · R01 · FY2021 · CA
Stromal Foxf2 suppresses prostate cancer progression
$493,644Li Xin · University Of Washington · R01 · FY2022 · CA
Targeting tumor-associated macrophages for triple-negative breast cancer treatment
$493,611Mingye Feng · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Exploiting a novel regulator of immunometabolism to enhance immunotherapy
$493,535Edward John Usherwood · Dartmouth College · R01 · FY2022 · CA
Exploiting a novel regulator of immunometabolism to enhance immunotherapy
$493,535Edward John Usherwood · Dartmouth College · R01 · FY2025 · CA
Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy
$493,522Weiqiang Chen · New York University · R01 · FY2024 · CA
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation
$493,468David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2025 · CA
Evaluation of Immune-based Combinations in Prostate Cancer
$493,445Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Neoadjuvant checkpoint blockade for recurrent glioblastoma
$493,424Robert M Prins · University Of California Los Angeles · R01 · FY2025 · CA
Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process.
$493,397Dennis Roop · University Of Colorado Denver · R01 · FY2024 · AR